Enveric Biosciences, Inc. (ENVB)
ENVB moved a median of -0.83% 30 minutes after news, and -2.14% by the close. How ENVB actually reacts to news — the realized, point-in-time move the market made, measured across 296 labeled events over the last three years with zero look-ahead.
ENVB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 278 |
| 30-min | -0.83% | 41% | 287 |
| 60-min | -0.90% | 40% | 293 |
| to close | -2.14% | 28% | 296 |
| Middle 50% of ENVB reactions | -3.49% to +1.45% |
|---|---|
| Median reaction (30-min) | -0.83% |
| Measured reactions | 296 |
Half of all Enveric Biosciences, Inc. news events land between -3.49% and +1.45% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ENVB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ENVB's baseline. Nothing else.
Recent ENVB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series | Press release | Business Wire | -1.34% | -2.01% | |
| Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference | Press release | Business Wire | +0.00% | -1.44% | |
| Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 | Press release | Business Wire | -3.90% | -3.90% | |
| Form 10-Q Enveric Biosciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.90% | -3.90% | |
| Form 8-K Enveric Biosciences, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -3.90% | -3.90% | |
| Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 | Press release | Business Wire | -2.53% | +5.70% | |
| Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development | Press release | Business Wire | +0.76% | +1.53% | |
| Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit | Press release | Business Wire | +0.00% | -4.51% | |
| Enveric Biosciences Announces Participation in 2026 BIO International Convention | Press release | Business Wire | +1.35% | -7.43% | |
| Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day | Press release | Business Wire | +1.45% | -7.51% | |
| Form 8-K Enveric Biosciences, For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | -7.51% | |
| Form 8-K Enveric Biosciences, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | -1.22% | |
| Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 | Press release | Business Wire | -0.86% | -4.72% | |
| Form S-8 Enveric Biosciences, | SEC filing · Form S-8 | SEC EDGAR | +2.68% | +0.89% | |
| Form 8-K Enveric Biosciences, For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +2.68% | +0.89% | |
| Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 | Press release | Business Wire | -3.99% | +3.94% | |
| Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 | Press release | Business Wire | -0.44% | +0.45% | |
| Form 10-Q Enveric Biosciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.44% | +0.45% | |
| Form 8-K Enveric Biosciences, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -0.44% | +0.45% | |
| Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders | Press release | Business Wire | +1.98% | -3.17% | |
| Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model | Press release | Business Wire | +4.01% | -0.29% | |
| Form D Enveric Biosciences, | SEC filing · Form D | SEC EDGAR | +4.01% | -0.29% | |
| Form 8-K Enveric Biosciences, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +2.27% | +6.68% | |
| Form DEFA14A Enveric Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +2.27% | +6.68% | |
| Form EFFECT Enveric Biosciences, | SEC filing · Form EFFECT | SEC EDGAR | +14.71% | +18.62% | |
| Form S-3 Enveric Biosciences, | SEC filing · Form S-3 | SEC EDGAR | +1.22% | +23.23% | |
| Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum | Press release | Business Wire | +2.33% | -1.75% | |
| Form 8-K Enveric Biosciences, For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +17.82% | -12.68% | |
| Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | Business Wire | +17.82% | -12.68% | |
| Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | Business Wire | -3.63% | -5.70% | |
| Form ARS Enveric Biosciences, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +2.52% | |
| Form DEF 14A Enveric Biosciences, For: Apr 14 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +2.52% | |
| Form DEFA14A Enveric Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +2.52% | |
| Form PRE 14A Enveric Biosciences, For: Apr 03 | SEC filing · Form PRE | SEC EDGAR | -3.81% | -5.24% | |
| Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates | Press release | Business Wire | -1.07% | +3.74% | |
| Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 | Press release | Business Wire | -0.55% | -1.65% | |
| Form 10-K Enveric Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.55% | -1.65% | |
| Form 8-K Enveric Biosciences, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | -1.65% | |
| Enveric Biosciences Announces Registration of Five Trademarks | Press release | Business Wire | — | +0.00% | |
| Enveric Biosciences Announces Withdrawal of Petition Against Its Patent | Press release | Business Wire | +3.18% | +9.09% | |
| Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data | Press release | Business Wire | -3.62% | -1.22% | |
| Form EFFECT Enveric Biosciences, | SEC filing · Form EFFECT | SEC EDGAR | +3.47% | +3.70% | |
| Form D Enveric Biosciences, | SEC filing · Form D | SEC EDGAR | +0.00% | -5.16% | |
| Form S-1 Enveric Biosciences, | SEC filing · Form S-1 | SEC EDGAR | +0.00% | +0.94% | |
| Form 8-K Enveric Biosciences, For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -1.28% | -10.21% | |
| Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option | Press release | Business Wire | -4.40% | -9.97% | |
| Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | Press release | Business Wire | -2.49% | -3.32% | |
| Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | Press release | Business Wire | -4.40% | -9.97% | |
| Form 8-K Enveric Biosciences, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -4.40% | -9.97% | |
| Form 8-K Enveric Biosciences, For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -2.43% | -2.30% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ENVB section they belong to.
Where else ENVB is measured.
ENVB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Enveric Biosciences, Inc.'s median reaction calculated?
Every labeled ENVB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 296 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of ENVB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ENVB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.